Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 1623Carcinoma, Renal Cell 501Urinary Bladder Neoplasms 460Carcinoma, Transitional Cell 232Breast Neoplasms 227Kidney Neoplasms 214Neoplasms 192Carcinoma, Non-Small-Cell Lung 172Colorectal Neoplasms 169Melanoma 163Ovarian Neoplasms 162Neoplasm Metastasis 144Lung Neoplasms 129Non-Muscle Invasive Bladder Neoplasms 105Pancreatic Neoplasms 103Stomach Neoplasms 100Uterine Cervical Neoplasms 91Squamous Cell Carcinoma of Head and Neck 84Endometrial Neoplasms 83Carcinoma, Hepatocellular 75Sarcoma 74Esophageal Neoplasms 71Head and Neck Neoplasms 70Triple Negative Breast Neoplasms 66Adenocarcinoma 64Colonic Neoplasms 53Testicular Neoplasms 51Urologic Neoplasms 46Wilms Tumor 44Liver Neoplasms 44

Interventions

darolutamide 1Pluvicto 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
High-Risk Localized Prostate Cancer × Genitourinary × 1 year × Clear all
NCT07450599 2026-05-13

CHINANEO

Bayer

Phase 2 Recruiting
250 enrolled
Genitourinary

High-Risk Localized Prostate Cancer

NCT07550517 2026-04-24

PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Not yet recruiting
60 enrolled
Genitourinary

High-Risk Localized Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡